Lloviu Virus: Genome Structure and Replication Mechanisms

Lloviu Virus: Genome Structure and Replication Mechanisms

The Lloviu virus (LLOV) is a member of the mononegaviruses, a group of viruses characterized by a single-stranded, non-segmented RNA genome of negative polarity. While LLOV was isolated in tissue culture, researchers have successfully determined nearly its entire genome, providing critical insights into how this virus functions and replicates within a host cell.

Key Facts

  • Genome Type: Linear, non-segmented, single-stranded RNA of negative polarity.
  • Genome Size: Approximately 19 kb in length.
  • Gene Count: Contains seven genes, though it likely produces only six mRNAs.
  • Entry Receptor: Utilizes Niemann-Pick C1 (NPC1) for intracellular entry.
  • Regulation: Transcriptional abundance is determined by the gene's proximity to the 3' end of the genome.

The LLOV Genome Architecture

The LLOV genome is a non-infectious strand of RNA that lacks a 5' cap and is not polyadenylated (meaning it does not have a poly-A tail). It is also not covalently linked to any protein. The genome likely possesses inverse-complementary termini at the 3' and 5' ends.

The genetic sequence is organized into seven specific genes. The order of these genes is: 3'-UTR → NP → VP35 → VP40 → GP → VP30 → VP24 → L → 5'-UTR. A notable distinction between LLOV and other filoviruses, such as ebolaviruses and Marburgviruses, is the way it expresses these proteins. While ebolaviruses and Marburgviruses synthesize seven distinct mRNAs, LLOV appears to produce only six. This suggests that one mRNA (VP24/L) is bicistronic, meaning a single mRNA molecule encodes two separate proteins.

Regarding its genetic markers, LLOV shares identical genomic transcriptional termination sites with ebolaviruses, differs from Marburgviruses in those sites, and possesses entirely unique transcriptional initiation sites.

[ไม่มีภาพประกอบ]

The Viral Replication Cycle

The life cycle of LLOV is a complex process of entry, transcription, and assembly. It begins when the virion attaches to specific receptors on the cell surface and is internalized. Once inside, the virion envelope fuses with the endosomal membranes, releasing the nucleocapsid (the protein shell protecting the RNA) into the cytosol.

Entry and Uncoating

For the virus to enter the cell successfully, the LLOV glycoprotein (GP) must be cleaved by cathepsins, which are endosomal cysteine proteases. Following this cleavage, the glycoprotein interacts with the intracellular entry receptor known as Niemann-Pick C1 (NPC1). Once the virus is in the cytosol, the RNA-dependent RNA polymerase (RdRp) partially uncoats the nucleocapsid to begin transcription.

Transcription and Protein Synthesis

The L protein binds to a single promoter at the 3' end of the genome. Transcription proceeds linearly; it may either stop after a specific gene or continue to the next. Because of this mechanism, genes located closer to the 3' end are transcribed more frequently than those toward the 5' end. This gradient serves as a natural form of transcriptional regulation.

The nucleoprotein (NP) is the most abundant protein produced. Its concentration within the cell acts as a trigger, signaling the L protein to switch from transcribing individual genes to replicating the entire genome.

Genome Replication and Budding

Replication involves the creation of full-length, positive-stranded antigenomes. These antigenomes then serve as templates to produce new negative-stranded progeny genomes. Finally, the newly synthesized genomes and structural proteins self-assemble near the inner cell membrane. The new virions bud off from the cell, acquiring their outer envelopes from the host's cellular membrane before moving on to infect other cells.

Summary of LLOV Genomic and Replication Features

Comparison of LLOV Genomic Characteristics
Feature LLOV Specification
Genome Length ~19 kb
RNA Polarity Negative (-)
Number of Genes 7
Number of mRNAs 6 (VP24/L is bicistronic)
Intracellular Receptor Niemann-Pick C1 (NPC1)
Protease Requirement Cathepsins

Frequently Asked Questions

How does LLOV differ from ebolaviruses in mRNA production?

While ebolaviruses produce seven mRNAs to express seven structural proteins, LLOV produces only six mRNAs, with the VP24 and L proteins likely being expressed from a single bicistronic mRNA.

What role does the NPC1 receptor play in LLOV infection?

The Niemann-Pick C1 (NPC1) receptor acts as the intracellular entry receptor. It interacts with the LLOV glycoprotein after the glycoprotein has been cleaved by endosomal cathepsins, allowing the virus to enter the cytosol.

How is the amount of protein produced regulated in LLOV?

Regulation is achieved through the position of the genes on the genome. Genes closer to the 3' end are transcribed more frequently, resulting in a higher abundance of proteins like the nucleoprotein compared to those at the 5' end.

What triggers the switch from transcription to replication?

The switch is determined by the concentration of the nucleoprotein (NP) in the cell. Once NP reaches a certain level, the L protein stops transcribing individual mRNAs and begins replicating the full-length genome.

Does the LLOV genome have a 5' cap or poly-A tail?

No, the LLOV genome does not possess a 5' cap and is not polyadenylated.

References

  1. Kuhn, J. H.; Becker, S.; Ebihara, H.; Geisbert, T. W.; Johnson, K. M.; Kawaoka, Y.; Lipkin, W. I.; Negredo, A. I.; Netesov, S. V.; Nichol, S. T.; Palacios, G.; Peters, C. J.; Tenorio, A.; Volchkov, V. E.; Jahrling, P. B. (2010). "Proposal for a revised taxonomy of the family Filoviridae: Classification, names of taxa and viruses, and virus abbreviations". Archives of Virology. 155 (12): 2083–2103. doi:10.1007/s00705-010-0814-x. PMC 3074192. PMID 21046175.
  2. Negredo, A.; Palacios, G.; Vázquez-Morón, S.; González, F. L.; Dopazo, H. N.; Molero, F.; Juste, J.; Quetglas, J.; Savji, N.; de la Cruz Martínez M; Herrera, J. E.; Pizarro, M.; Hutchison, S. K.; Echevarría, J. E.; Lipkin, W. I.; Tenorio, A. (2011). Basler, Christopher F (ed.). "Discovery of an Ebolavirus-Like Filovirus in Europe". PLOS Pathogens. 7 (10) e1002304. doi:10.1371/journal.ppat.1002304. PMC 3197594. PMID 22039362.
  3. "ICTV Taxonomy History for Lloviu cuevavirus". International Committee on Taxonomy of Viruses. Retrieved 7 March 2015.
  4. Heinz Feldmann; Friederike Feldmann; Andrea Marzi (2018). "Ebola: Lessons on Vaccine Development". Annual Review of Microbiology. 72: 423–46. doi:10.1146/annurev-micro-090817-062414. PMC 11059209. PMID 30200851. S2CID 52185735.
  5. Ramírez de Arellano, Eva; Sanchez-Lockhart, Mariano; Perteguer, Maria J.; Bartlett, Maggie; Ortiz, Marta; Campioli, Pamela; Hernández, Ana; Gonzalez, Jeanette; Garcia, Karla; Ramos, Manolo; Jiménez-Clavero, Miguel Ángel (19 April 2019). "First Evidence of Antibodies Against Lloviu Virus in Schreiber's Bent-Winged Insectivorous Bats Demonstrate a Wide Circulation of the Virus in Spain". Viruses. 11 (4): 360. doi:10.3390/v11040360. ISSN 1999-4915. PMC 6521100. PMID 31010201.